FDA
-
-
-
-
-
-
-
Relmada Therapeutics (RLMD) Reports Positive Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential
-
-
-
-
-
-
-
Relmada Therapeutics (RLMD) granted FDA Orphan Drug Designations for treatment of Amyotrophic lateral sclerosis
-
-
-
-
-
-
-
Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting
-
-
-
-
-
-
-
Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder
-
-
-
-
-
-
-
Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs
-
-
-
-
-
-
-
Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression
-
-
-
-
-
-
-
Relmada Therapeutics Inc. (RLMD) Reports Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
-
251,638 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All